- Testimony of M. Isabelle Chaudry: Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety
Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety Before the Subcommittee on Health of the House Committee on Energy and Commerce
December 4, 2019
Thank you for the opportunity to testify. My name is M. Isabelle Chaudry and I am the Senior Policy Manager at the National Women’s Health Network, a D.C. – ...
- FDA Meeting – Agile transdermal contraceptive patch AG200-15
Testimony Delivered at the Meeting of the FDA Bone, Reproductive and Urologic Drugs Advisory Committee
October 30, 2019
Thank you for the opportunity to speak on the Agile transdermal contraceptive patch AG200-15. Being able to space, plan, and prevent pregnancy is vital to women’s health. We appreciate the agency’s interest in fostering the development of ...
- FDA Comments – Draft Guidance for Hormonal Contraceptive Products
September 10, 2019
FDA-2019-D-2153-0002]
The Honorable Norman E. Sharpless, M.D.
Acting Commissioner of Food and Drugs
Food and Drug Administration
Division of Dockets Management (HFA-305)
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852
Submitted electronically
Dear Dr. Sharpless:
Thank you for the opportunity to comment on recently released guidance for safe and effective hormonal contraception. Being able to space, plan, and prevent pregnancy is vital ...
- FDA Meeting – Surgical Mesh for Transvaginal Repair of Pelvic Organ Prolapse
Testimony Delivered at the Meeting of the FDA Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee
February 12, 2019
My name is Cindy Pearson, and I am the executive director of the National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health ...
- FDA Meeting – Risk Benefit Assessment
Testimony Delivered at the FDA Public Meeting on Benefit-Risk Assessments in Drug Regulatory Decision-Making
September 18, 2017
My name is Caila Brander and I am the Policy Coordinator at The National Women’s Health Network, a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and, ...
- FDA Meeting – Off-Label Use of Medical Products
Testimony Delivered at the FDA Public Meeting on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products
November 10, 2016
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and do not accept financial support from ...
- FDA Comments – Real World Evidence & Essure
Comments on the Draft Guidance: Use of Real-World Evidence to Support Regulatory Decision Making for Medical Devices
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and do not accept financial support from insurance companies, drug companies or medical ...
- FDA Scientific Workshop – Labeling of Low-dose Vaginal Estrogen Products
Statement of Cindy Pearson, Executive Director, National Women’s Health Network
Food and Drug Administration Scientific Workshop on Labeling Lower-Dose Estrogen-Alone Products for Symptoms of Vulvar and Vaginal Atrophy
My name is Cindy Pearson, and I am the Executive Director of The National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to ...
- FDA Scientific Workshop – Drug Interactions with Hormonal Contraceptives
Statement of Christina Cherel, Program Coordinator, National Women’s Health Network
Food and Drug Administration Hormal Contraception Public Workshop on Drug Interactions with Hormonal Contraceptives: Public Health and Drug Development Implications
My name is Christina Cherel, and I am the Program Coordinator at the National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that ...
- FDA Meeting – Osteoporosis Drug Development
Statement of Christina Cherel, Program Coordinator, National Women’s Health Network
Food and Drug Administration Meeting of the Division of Bone, Reproductive, and Urologic Products in the Center for Drug Evaluation and Research.
“Osteoporosis Drug Development: Moving Forward”
My name is Christina Cherel, and I am the Program Coordinator at The National Women’s Health Network. The National Women’s Health Network ...
- FDA Meeting – Essure
Testimony Delivered at the Meeting of the FDA Meeting of the Obstetrics and Gynecology Devices Panel
September 24, 2015
My name is Cindy Pearson, and I am the Executive Director of The National Women’s Health Network. The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We are ...
- FDA Meeting – Generic Drug Labeling
Statement of Coco Jervis, J.D., Program Director
Food and Drug Administration Public Meeting on Supplemental Applications Propsing Labeling Changes for Approved Drugs and Biological Products
March 27, 2015
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory ...
- FDA Scientific Workshop – Female Sexual Interest/Arousal Disorder
Statement of Cindy Pearson, Executive Director, National Women’s Health Network
Food and Drug Administration Scientific Workshop on Female Sexual Interest/Arousal Disorder
I am speaking on behalf of the National Women’s Health Network, a non-profit advocacy organization that works to improve the health of all women. We are supported by our members, and do not take financial contributions ...
- FDA Meeting – Lorcaserin
Statement of Kate Ryan
Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Meeting on Lorcaserin
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take ...
- FDA Meeting – Qnexa Safety and Efficacy
Statement of Kate Ryan
Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee Meeting
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to policy and regulatory decision-making bodies. We are supported by our members and do not take financial contributions from ...
- FDA Meeting – Naltrexone/Bupropion (Contrave)
Statement of Kate Ryan, Program Coordinator
Food and Drug Administration (FDA) Gastroenterology Endocrinologic and Metabolic Drugs Advisory Committee
The National Women’s Health Network is a nonprofit advocacy organization that works to improve the health of all women. We bring the voices of women consumers to the policy and regulatory decisionmaking bodies. We are supported by our members and ...
